REGN shows evidence of a price recovery underway as illustrated by momentum indicators and volumn oscillator on the daily. This is further backed up by encouraging signals on both lower and highe timeframes.Trade active
Quarterly result dissappointed esp with Eyleas facing biosimilar competition. However the company has growth prospects elsewhere and price quickly recovered. I had considered exiting at a loss but momentum indiicator was not bearish and fortunately it paid offTrade closed manually
The stock yo-yoed between profit and loss and I finally closed my positions at about net break even, fortunately prior to mixed data for their Phase 3 itepekimab
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.